Basilea Pharmaceutica AG
0QNA.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$943.72M
Close$
$55.38
14.3% downside
Current Fair Value
14.3% downsideOvervalued by 14.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $943.72 Million |
|---|---|
| Enterprise Value | $852.76 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $3.29 |
| Beta | 0.42 |
| Outstanding Shares | 12,370,195 |
Return
| Return on Equity | 72.13% |
|---|---|
| Return on Assets | 39.29% |
| Return on Invested Capital | 48.13% |
Valuation & Multiples
| P/E Ratio | 15.38 |
|---|---|
| PEG | 6.06 |
| Price to Sales | 1.9 |
| Price to Book Ratio | 4.97 |
| Enterprise Value to Revenue | 1.98 |
| Enterprise Value to EBIT | 6.91 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$3.34
Average shareholder expectationRevenue Estimate
$107.70 M
Average shareholder expectationNext Earnings Call
Expected Date
February 16, 2027
EPS Estimate
$2.88
Average shareholder expectationRevenue Estimate
$148.35 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Basilea Pharmaceutica AG
189 employees
CEO: David Veitch Basilea Pharmaceutica AG is a revenue-generating biopharmaceutical company dedicated to developing innovative products to meet critical medical needs in both cancer treatment (oncology) and the fight against infections (anti-infectives)....